Why VA-ECMO should not be used routinely in AMI-Cardiogenic Shock

This review summarizes the current evidence regarding efficacy and safety of venoarterial extracorporeal membrane oxygenation (VA-ECMO) in the setting of cardiogenic shock. Currently, there is evidence from 4 randomized controlled trials which all do not support a mortality benefit and increased complication rates by VA-ECMO. Based on current evidence, possible subgroups will be discussed and indications in selected very small patient groups be discussed.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Perspective Source Type: research